Short Term Outcome of Primary Percutaneous Coronary Interventions; Ten years registry

Thesis Submitted by

Ahmed Ibrahim Soliman Eissa, M.Sc.

In Partial Fulfillment of
MD Degree in Critical Care

Supervisors

Prof. Dr. Alia Abdel-Fattah, MD
Prof. of Critical Care,
Critical Care Department,
Cairo University

Prof. Dr. Faheem Ragab, MD
Prof. of Critical Care,
Critical Care Department,
Cairo University

Dr. Ahmed Abdel-Aziz, MD
Ass. Prof. of Critical Care,
Critical Care Department,
Cairo University

Dr. Mahmoud El-Badry, MD
Ass. Prof. of Critical Care,
Critical Care Department,
Cairo University

Cairo University

2009

Abstract

The efficiency & safety of primary PCI in managing pts with acute MI is well established. Critical care department of Cairo University encompasses a well equipped catheter lab & well trained staff; readily available 24 hrs all through the 7 days of the week. Fourhanded & twenty pts presented with acute MI were managed with primary PCI, over almost 10 years with success rate 93.52% & outcome similar to that of international centers. Six months outcome of 207 pts was similar to that of international centers.

Key Word: PCI, Primary PCI, Registry, Acute MI

Acknowledgement

Thanks to ***Prof. Dr. Sherif Mokhtar,*** our Master mind, I always owe him much. He offered us not only the idea to complete this work but also the spirit of being eager to gain more experience and skills. Through his meticulous review of all details we learned a lot. Words are not sufficient to express my deep gratitude for him.

I would like to express my deepest gratitude and highest appreciation to ***Prof. Dr. Alia Abdel-Fattah***, for her continuous support and direct supervision to achieve progress in this thesis. I would specially thank her for active contribution in the nuclear part of this work. I owe her much.

Special thanks must be given to ***Prof. Dr. Faheem Ragab,*** for his encouragement and support during the practical and theoretical work. Being the director of critical care centre, this work can not be conducted without his great help. I owe him much.

Many thanks to ***Dr. Ahmed Abdel-Aziz,*** for his guidance, continuous support and contribution in the interventional part of this work. He was always helpful and supportive and taught me the systematic way of thinking.

1 would like to express my deepest gratitude to ***Dr. Mahmoud Al-Badry***, who supervised this work with great interest. He was generous in devoting enough time and effort for revision and constructive criticism.

e has a great contribution in the interventional & follow up parts of this ork.

A special acknowledgement for ***Prof. Dr Hassan Khalid***, head of itical care department for his support and encouragement. I owe him uch.

I would like to express my thanks & my great gratefulness to my lleagues in critical care department; ***Dr. Mohammed Fawzy, Dr. asser Nassar, Dr. Akram Abdel-Bary*** & ***Dr. Mahmoud Khalid*** for their pport and great help.

I am very grateful to critical care department staff, cath. lab team & clear lab team; they are the real owner of this work.

Contents

Introduction 1

Aim of The Work 6

Review of Literature 7

Chapter I: Reperfusion therapy in acute STEMI 7

Chapter II: Optimal and suboptimal reperfusion 51

Chapter III: Assessment of outcome post-MI 85

Patients & Methods 109

Results 127

Discussion 170

Summary 188

Conclusion 194

References 196

Arabic Summary 5-1

List of Abbreviations

%DS	**:**	Percent Diameter Stenosis
ACC	**:**	American Collage of Cardiology
ACCP	**:**	American College of Chest Physicians
ACE	**:**	Angiotensin Converting Enzyme
ACS	**:**	Acute Coronary Syndrome
ACT	**:**	Activated Clotting Time
AHA	**:**	American Heart Association
AIVR	**:**	Accelerated Idio-Ventricular Rhythm
ASNC	**:**	American Society of Nuclear Cardiology
BMS	**:**	Bare Metal Stents
CABG	**:**	Coronary Artery Bypass Grafting
CAD	**:**	Coronary Artery Disease
CCTA	**:**	Coronary CT Angiography
CHB	**:**	Complete heart block
CK	**:**	Creatine Kinase
CMRI	**:**	Cardiac Magnetic Resonance Imaging
CT	**:**	Computed Tomography
cTnI	**:**	cardiac Troponin I
cTnT	**:**	cardiac Troponin T
CVS	**:**	CerebroVascular Stroke
DES	**:**	Drug-Eluting Stents
DM	**:**	Diabetes Mellitus
DBP	**:**	Diastolic Blood Pressure
DTBT	**:**	Door-To-Balloon Time
EBCT	**:**	Electron Beam Computed Tomography

ECG	**:**	Electrocardiography
EDP	**:**	End-Diastolic Pressure
ESC	**:**	European Society of Cardiology
FPA	**:**	Fibrino-Peptide A
GPIIb/IIIa	**:**	Platelet Glyco-Protein IIb/IIIa Receptors
HF	**:**	Heart Failure
HTN	**:**	Hypertension
IABP	**:**	Intra-Aortic Balloon Pump
IRA	**:**	Infarct Related Artery
IV	**:**	Intra-Venous
IVUS	**:**	Intra-Vascular Ultra-Sound
JCIA	**:**	Joint Commission International Accreditation
LAD	**:**	Left Anterior Descending artery
LBBB	**:**	Left Bundle Branch Block
LCX	**:**	Left Circumflex Artery
LV	**:**	Left Ventricle
LVEF	**:**	Left Ventricular Ejection Fraction
MACE	**:**	Major Adverse Cardiac Events
MDCT		Multi-Detector CT
MI	**:**	Myocardial Infarction
MLD	**:**	Minimal Luminal Diameter
MPI	**:**	Myocardial Perfusion Imaging
MRI	**:**	Magnetic Resonance Imaging
MSCT	**:**	Multi-Slice CT
nPA	**:**	Lanoteplase
NSTEMI	**:**	Non ST Elevation Myocardial Infarction
PAI-1	**:**	Plasminogen Activator Inhibitor 1
PCI	**:**	Percutaneous Coronary Intervention

PES	**:**	Paclitaxel-Eluting Stents
PET scan	**:**	Positron Emission Tomography scanning
PTCA	**:**	Percutaneous Trans-luminal Coronary Angioplasty
QCA	**:**	Quantitative Coronary Angiography
RCA	**:**	Right Coronary Artery
RNA	**:**	Radio-Nuclide Angiography
rPA	**:**	recombinant Plasminogen Activator
RV	**:**	Right Ventricle
RVD	**:**	Reference Vessel Diameter
SDS	**:**	Summed Difference Score
SK	**:**	StreptoKinase
SL	**:**	Sub- Lingual
SDS	**:**	Summed Difference Score
SES	**:**	Sirolimus-Eluting Stents
SPECT	**:**	Single Photon Emission Computed Tomography
SRS	**:**	Summed Rest Score
SSS	**:**	Summed Stress Score
STEMI	**:**	ST-segment Elevation Myocardial Infarction
SVT	**:**	Supra-Ventricular Tachycardia
Tc-99m	**:**	Technetium 99m
TIMI	**:**	Thrombolysis In Myocardial Infarction
TMP	**:**	TIMI Myocardial Perfusion
TNK-tPA	**:**	Tenecteplase
tPA	**:**	tissue-type Plasminogen Activator
TVR	**:**	Target Vessel Revascularization
VF	**:**	Ventricular Fibrillation
VT	**:**	Ventricular Tachycardia

List of Abbreviations of clinical trial

ACC-NCDR	:	The American Collage of Cardiology (ACC) National Cardiovascular Data Registry
AIR PAMI	:	AIR Primary Angioplasty in Myocardial Infarction trial
AKUH	:	Aga Khan University Hospital
AMI-SK	:	Acute Myocardial Infarction- StreptoKinase trial
APEX-AMI	:	Assessment of PEXelizumab in Acute Myocardial Infarction trial
ASSENT	:	ASsessment of the Safety and Efficacy of New Thrombolytic regimens trial
CAPTIM	:	Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction trial
CADILLAC	:	The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial
CLARITY	:	CLopidogrel as Adjunctive ReperfusIon TherapY
COMMIT	:	ClOpidogrel & Metoprolol in Myocardial Infarction Trial
DANAMI	:	DANish trial in Acute Myocardial Infarction
FAME	:	Fractional flow reserve versus Angiography for Multi-vessel Evaluation
FINESSE trial	:	Facilitated INtervention with Enhanced reperfusion Speed to Stop Events trial
GRACIA	:	Grupo de Análisis de la Cardiopatía Isquémica Aguda (Randomized trial comparing stenting within 24 hours of thrombolysis versus ischemia-guided approach to thrombolysed acute myocardial infarction with ST

		elevation)
GUSTO trial	:	Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries
INJECT trial	:	INternational Joint Efficacy Comparison of Thromolytics
InTIME trial	:	Intravenous nPA for the Treatment of Infracting Myocardium Early
NRMI	:	National Registry of Myocardial Infarction
PACT	:	Pravastatin in Acute Coronary Treatment
PAMI	:	Primary Angioplasty in Myocardial Infarction study
PRAGUE	:	PRimary Angioplasty in patients transferred from General community hospitals to specialized PTCA Units with or without Emergency thrombolysis
RAPID trial	:	Reduced Anti-platelet therapy with PImecrolimus Drug-eluting stent trial
SHOCK trial	:	SHould we emergently revascularize Occluded coronaries for Cardiogenic Shock
SIRIUS	:	SIRolImus-eluting versus Uncoated Stents
SPEED	:	Strategies for Patency Enhancement in the Emergency Department
STENT PAMI	:	STENT Primary Angioplasty in Myocardial Infarction
TAXUS IV	:	pacliTAXel-eluting versus Uncoated Stents in percutaneous coronary intervention
TIMI	:	Thrombolysis In Myocardial Infarction
TRITON	:	TRials to assess Improvement in Therapeutic Outcomes by optimizing platelet iNhibition with prasugrel
TYPHOON		Trial to assess the use of the cYPHer stent in acute myocardial infarction treated with ballOON angioplasty

List of Tables

Table	Page
Table (1): ACC/AHA guidelines: Chest pain duration and selecting reperfusion strategy	**4**
Table (2): Preferred thrombolytic regimens for acute STEMI	**8**
Table (3): ACC/AHA/SCAI guidelines for selecting PCI for reperfusion therapy in patients with STEMI	**21**
Table (4): ACC/AHA guidelines: Indications of IABP in acute MI	**48**
Table (5): ACC/AHA guideline Summary: Indications of CABG in patients with STEMI	**50**
Table (6): Differentiation between hibernation and stunning	**82**
Table (7): Zwolle risk index for 30-day mortality after primary PCI	**87**
Table (8): Efficacy of the different methods of stress testing in specific clinical settings	**96**
Table (9): Number of patients per year	**128**
Table (10): ECG diagnosis of the site of infarction	**130**
Table (11): Clinical condition and basic rhythm among the studied patients prior to PCI	**131**
Table (12): Number of diseased vessels among the studied patients	**133**
Table (13): Infract-related artery that was subjected to intervention	**134**
Table (14): The site of lesion subjected to PCI	**135**
Table (15): Baseline QCA parameters in the studied pts	**136**
Table (16): TIMI flow in IRA in the studied pts	**137**
Table (17): Causes of failure of angioplasty	**138**
Table (18): Different modalities of coronary intervention	**140**
Table (19): **Conjoint use of thrombolytic therapy**	**141**
Table (20): Devices used during the procedure	**141**
Table (21): Balloon data	**144**

Table (22): Stent data	**144**
Table (23): Stent type	**145**
Table (24): Post PCI QCA parameters among the studied pts	**146**
Table (25): Post PCI TIMI flow in IRA among the studied pts	**146**
Table (26): Markers of reperfusion following PCI	**150**
Table (27): In-hospital MACE following primary PCI	**152**
Table (28): Zwolle risk index and in-hospital mortality	**153**
Table (29): Association between risk factors for CAD & MACE	**154**
Table (30): Association between time to PCI & MACE	**155**
Table (31): Association between cardiogenic shock & MACE	**156**
Table (32): Association between IRA & MACE	**157**
Table (33): Association between site of lesion & MACE	**158**
Table (34): Association between intra-coronary thrombi & MACE	**159**
Table (35): Association between type of intervention & MACE	**160**
Table (36): Association between the use of thrombolytics & MACE	**161**
Table (37): Six months MACE after PCI	**162**
Table (38): Six months scintigraphic follow up	**164**
Table (39): Severity of ischemia in patients with positive MPI	**165**
Table (40): Predictors of six months MACE	**166**
Table (41): Association between DM & Scintigraphic follow up	**167**
Table (42): Post PCI QCA parameters among the studied pts	**168**
Table (43): Association between DM & angiographic re-stenosis	**169**
Table (44): Baseline demographic and clinical characteristics; compared with other studies	**174**
Table (45): Comparison of angiographic and procedural details	**176**
Table (46): Overall success rate of different studies	**178**
Table (47): Mortality in major trials and registries of primary PCI	**180**
Table (48): The Incidence of re-infarction in different studies	**181**

Table (49): Incidence of MACE in patients with cardiogenic shock complicating MI	**182**
Table (50): In-hospital mortality in current study and in Zwolle study	**183**

List of Figures

Figure	Page
Figure (1): ACC/AHA Algorithm for initial management of patients with acute ST elevation myocardial infarction	2
Figure (2): Time to thrombolysis and 35-day mortality	24
Figure (3): Clopidogrel timing and benefit before stenting	45
Figure (4): Factors potentially influencing TIMI grade flow	52
Figure (5): Infarct size measured by sestamibi predicts mortality	66
Figure (6): Coronary artery dissection after angioplasty	70
Figure (7): Edge detection on quantitative coronary angiography	78
Figure (8): Flow-function relationship in hibernating and stunned myocardium	81
Figure (9): LVEF as a predictor of one-year mortality after STEMI	92
Figure (10): Choice of exercise testing modality in different clinical settings	95
Figure (11): Acolysis device & probe tip	115
Figure (12): X-SIZER catheter system: drive unit, catheter shaft, aspiration tubing, inline filter, and vacuum bottle	117
Figure (13): Twenty segment scoring system	122
Figure (14): Calculation of tests of performance	126
Figure (15): Number of patients per year	128
Figure (16): Gender of the studied patients	129
Figure (17): Risk factors of CAD among the studied patients	129
Figure (18): ECG diagnosis of the site of infarction	130
Figure (19): Clinical condition and basic rhythm among the studied patients prior to PCI	132
Figure (20): Number of diseased vessels among the studied patients	133
Figure (21): Infarct-related artery that was subjected to intervention	134

Figure (22): The site of lesion subjected to PCI	**135**
Figure (23): Degree of coronary obstruction among the studied pts	**136**
Figure (24): TIMI flow in IRA in the studied pts	**137**
Figure (25): Success rate of angioplasty	**138**
Figure (26): Incidence of failure of PCI per year	**139**
Figure (27): Different modalities of coronary intervention	**140**
Figure (28): IUT, primary PTCA and stenting for total LCx occlusion	**142**
Figure (29): Stent types used in treated lesions	**145**
Figure (30): Incidence of procedural complications	**147**
Figure (31): Primary PCI to LAD total occlusion with complete restoration of normal TIMI III flow	**148**
Figure (32): Primary PCI to LCx total occlusion with complete restoration of normal TIMI III flow	**149**
Figure (33): CK level before and after PCI	**150**
Figure (34): CK-MB level before and after PCI	**151**
Figure (35): ST segment elevation before and after PCI	**151**
Figure (36): In-hospital MACE following primary PCI	**152**
Figure (37): Association between risk factors for CAD & MACE	**154**
Figure (38): Association between time to PCI & MACE	**155**
Figure (39): Association between cardiogenic shock & MACE	**156**
Figure (40): Association between IRA & MACE	**157**
Figure (41): Association between site of lesion & MACE	**158**
Figure (42): **Association between intra-coronary thrombi & MACE**	**159**
Figure (43): **Association between type of intervention & MACE**	**160**
Figure (44): Association between the use of thrombolytics & MACE	**161**
Figure (45): Six months MACE after PCI	**163**
Figure (46): Six months Scintigraphic follow up	**165**
Figure (47): Association between DM & Scintigrpahic follow up	**167**